Lantronix's new partnership to develop edge AI threat detection systems for drones has spotlighted the stock, but analysts are divided on whether its current valuation fully prices in the risks and opportunities of the nascent defense tech market.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.
The home improvement giant is eliminating approximately 800 corporate positions and mandating a full-time return to office, while simultaneously launching new AI tools for professionals and expanding its organic seed offerings nationwide, signaling a dual focus on operational efficiency and future-facing customer engagement.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
While Boeing's Q4 revenue beat offers short-term relief, analysts point to its unprecedented order backlog as the true indicator of long-term recovery and growth potential in the commercial aviation sector.
As Smurfit Westrock navigates the complex post-merger landscape, its share price tells a conflicted story. While recent gains hint at optimism, a deeper look reveals a stock trading at a significant discount to some intrinsic value models, even as its P/E ratio suggests a premium. The market appears to be weighing integration execution risks against long-term synergy potential.
A reported fiery exchange between JPMorgan's Jamie Dimon and Coinbase's Brian Armstrong at the World Economic Forum lays bare the intensifying battle between traditional finance and the crypto industry over regulation, deposits, and the future of money.
Meta CEO Mark Zuckerberg's forecast of a major AI infrastructure build-out through 2026 suggests continued robust spending on Nvidia's hardware, reinforcing the chipmaker's central role in the ongoing tech boom.
The Biden administration has approved a major arms sale to Israel, featuring attack helicopters and armored vehicles, amid a fragile ceasefire in Gaza and ongoing scrutiny over U.S. military support.
In a rare firsthand account, Dr. Mohamed Ibrahim details his three-day escape from el-Fasher as paramilitary forces overran the city. His testimony paints a harrowing picture of urban warfare, civilian slaughter, and the systematic collapse of Sudan's last army bastion in Darfur.
Exclusive testimony from Dr. Mohamed Ibrahim, who fled the last hospital in Sudan's strategic el-Fasher, details a three-day ordeal of hiding from paramilitary forces, witnessing mass casualties, and surviving a kidnapping and ransom demand—shedding light on a siege the U.N. calls a 'massive crime scene.'
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Amid a brutal year for apparel stocks, Deckers Outdoor delivered a stunning earnings beat, sending shares soaring 19%. The performance of its HOKA and UGG brands, coupled with raised guidance, suggests Wall Street's pessimism may have been overblown for this long-term winner.
Inditex (BME:ITX) shares have taken a breather, trading flat over the past week after a robust multi-year performance. With the stock slightly below analyst targets, investors are weighing whether the current price offers value or if the growth momentum is cooling.
Despite a stellar 38% gain over the past year, analysis suggests Federated Hermes (NYSE: FHI) shares may still be trading at a discount to their intrinsic value, presenting a potential opportunity in the capital markets sector.
Victoria's Secret shares have surged nearly 50% in the past year, leaving investors to grapple with a critical question: Is the rally justified, or has the market gotten ahead of itself? A deep dive into the numbers reveals a complex picture where traditional valuation models clash.
Fair Isaac Corporation (FICO), the analytics software giant behind the ubiquitous credit score, has seen its shares retreat from multi-year highs. This pullback has investors debating whether the dip presents a rare entry point or signals that the stock's premium valuation is finally facing a reality check.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
Equity Residential's stock performance has been mixed, lagging behind long-term benchmarks. A detailed analysis of its discounted cash flow and peer comparisons suggests the apartment REIT may be trading at a significant discount to its intrinsic value, presenting a potential opportunity as market dynamics evolve.
